Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatology
Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will be chaired by Dr. Lawrence Eichenfield, chief of pediatric and adolescent dermatology at Rady Children’s Hospital–San Diego, vice chair of the Department of Dermatology and professor of dermatology and pediatrics at the University of California, San Diego School of Medicine.
Dr. Eichenfield is an internationally recognized leader in dermatology, whose career has been devoted to improving the care of patients with skin disease. He has been directly involved in the development of novel topical acne, eczema and psoriasis products, and has an appreciation for the regulatory challenges in the development and launch of new chemical entities. He directs the largest pediatric dermatology clinical trials program in the country and holds leadership roles with key professional associations, making him a significant voice for innovation in dermatology.
“I am pleased to be joining and leading Novan’s new Advisory Council,” said Dr. Eichenfield. “The anti-infective and immunomodulatory effects of nitric oxide have long been documented in the literature. I believe Novan’s nitric oxide-releasing platform has the potential to deliver on the promise of nitric oxide, and I am happy to join my dermatology colleagues in advising this company in their pursuit of innovative treatment options for skin conditions with significant unmet need.”
“Our new Advisory Council has a deep appreciation for the potential of nitric oxide as an endogenous regulator of inflammation and broad-spectrum antimicrobial to treat skin diseases,” said Dr. M. Joyce Rico, board-certified dermatologist and Chief Medical Officer of Novan. “Novan is committed to developing and commercializing novel, first-in-class therapies from our nitric oxide-releasing platform. We believe this esteemed panel will enhance the strength of our current product-development programs and will bring both pragmatic and creative approaches to the discussion of novel opportunities across the Novan pipeline.”
The founding members of Novan’s Advisory Council, along with their respective therapeutic areas of expertise relevant to the Company’s development pipeline, are:
- Lawrence Eichenfield, MD; Chairman, Acne and Inflammatory Skin Diseases
- James Del Rosso, DO; Acne
- Diane Thiboutot, MD; Acne
- Ted Rosen, MD; Antiviral
- Brian Berman, MD, PhD; Antiviral
- Leon Kircik, MD; Antifungal
- Alan Menter, MD; Inflammatory Skin Diseases
- Lisa Beck, MD; Inflammatory Skin Diseases
Detailed biographies for each of the members can are on the Novan website.